Dare Bioscience, Inc. (DARE) Q4 2025 Earnings Call

Investor webinar replay

Watch the replay and follow the connected company analysis, news, and investor updates for Dare Bioscience, Inc..

Watch the replay

Replay transcript excerpt

WEBVTT 00:00:00.031 -- 00:00:05.499 Welcome to the conference call hosted by Dairy Bioscience to review the company's 2025 00:00:05.499 -- 00:00:10.386 financial results and to provide a business update. 00:00:10.386 -- 00:00:16.114 This call is being recorded. My name is Desiree and I will be your operator today. 00:00:16.114 -- 00:00:20.620 With us today from Dairy are Sabrina Martucci-Johnson, 00:00:20.620 -- 00:00:26.469 President and Chief Executive Officer, and Marty Haring-Layton, Chief Accounting Officer. 00:00:26.469 -- 00:00:29.731 Ms. Haring-Layton, please proceed. 00:00:29.731 -- 00:00:34.137 Good afternoon and welcome to the DARE Bioscience Financial Results and Business Update 00:00:34.137 -- 00:00:37.242 Call for the year-ended December 31, 2025. 00:00:37.242 -- 00:00:42.349 Today, we will review our financial results, provide updates on our clinical pipeline, 00:00:42.349 -- 00:00:46.275 and discuss the continued execution of our expanded business strategy. 00:00:46.275 -- 00:00:51.863 That strategy includes a dual-path approach, commercializing proprietary formulations 00:00:51.863 -- 00:00:56.945 through 503 compounding while pursuing FDA approval, and advancing select 00:00:56.945 -- 00:01:01.914 solutions as branded consumer health products that do not require a prescription. 00:01:01.914 -- 00:01:07.243 In all cases, our goal is to bring innovative women's health solutions to market as efficiently 00:01:07.243 -- 00:01:11.891 and quickly as possible. I would like to remind you that today's discussion will include 00:01:11.891 -- 00:01:15.978 forward-looking statements within the meaning of federal securities laws, which are made 00:01:15.978 -- 00:01:20.225 pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act 00:...